NCT07121374View on ClinicalTrials.gov

NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 22, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

July 31, 2029

Conditions
Pleural Epithelioid MesotheliomaMesothelioma; PleuraNeoadjuvant Chemoimmunotherapy
Interventions
DRUG

Neoadjuvant chemo-immunotherapy

Neoadjuvant chemotherapy (2 cycles of cisplatin OR carboplatin accord healthcare- investigator's choice - PLUS pemetrexed fresenius AND immunotherapy (2 cycles of Opdivo PLUS 1 cycle of Yervoy for inoperable T2-T3 TNM 9 patients with PM

PROCEDURE

Extended pleurectomy/decortication in case of reaching operability

After the systemic treatment the surgery will follow if patient is operable.

Trial Locations (1)

2650

RECRUITING

University Hospital Antwerp, Edegem

All Listed Sponsors
collaborator

University Hospital, Ghent

OTHER

collaborator

Kom Op Tegen Kanker

OTHER

lead

University Hospital, Antwerp

OTHER

NCT07121374 - NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study | Biotech Hunter | Biotech Hunter